Literature DB >> 9451718

Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration.

P Barbier1, A Colelli, R Maggio, D Bravi, G U Corsini.   

Abstract

Pergolide is an ergotamine derivative with potent D1 and D2 receptor activity. In this study we showed that pergolide binds tightly to dopamine D2 short receptors, as indicated by the long period of occupancy of the receptors after washing. Furthermore, pergolide induces receptor internalization to a larger extent than dopamine, seeing that no recycling of the receptors to the plasma membrane was observed for either agonist. The dissociation of pergolide from dopamine receptors occurs during the endocytotic process, leaving the receptors accessible to [3H]methylspiperone. Pergolide is a lipophilic compound that can reach and compete with [3H]methylspiperone for binding to sequestered receptors. If internalized receptors are still a target for drug action, pergolide could be a suitable compound of therapeutic interest in cases where receptor sequestration could prevent dopamine efficacy, as in levodopa therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9451718     DOI: 10.1007/BF01285554

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  15 in total

1.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

Review 2.  Structures of dopamine receptors.

Authors:  B F O'Dowd
Journal:  J Neurochem       Date:  1993-03       Impact factor: 5.372

3.  Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization.

Authors:  S S Yu; R J Lefkowitz; W P Hausdorff
Journal:  J Biol Chem       Date:  1993-01-05       Impact factor: 5.157

Review 4.  Dopamine receptor pharmacology.

Authors:  P Seeman; H H Van Tol
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

5.  Agonist-induced desensitization of muscarinic receptor-mediated calcium efflux without concomitant desensitization of phosphoinositide hydrolysis.

Authors:  S B Masters; M T Quinn; J H Brown
Journal:  Mol Pharmacol       Date:  1985-03       Impact factor: 4.436

6.  Agonist-induced alteration in the membrane form of muscarinic cholinergic receptors.

Authors:  T K Harden; L A Petch; S F Traynelis; G L Waldo
Journal:  J Biol Chem       Date:  1985-10-25       Impact factor: 5.157

7.  Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells.

Authors:  M Itokawa; M Toru; K Ito; H Tsuga; K Kameyama; T Haga; T Arinami; H Hamaguchi
Journal:  Mol Pharmacol       Date:  1996-03       Impact factor: 4.436

8.  Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist.

Authors:  L Lemberger; R E Crabtree
Journal:  Science       Date:  1979-09-14       Impact factor: 47.728

9.  Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor.

Authors:  G Y Ng; B Mouillac; S R George; M Caron; M Dennis; M Bouvier; B F O'Dowd
Journal:  Eur J Pharmacol       Date:  1994-03-15       Impact factor: 4.432

10.  A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.

Authors:  C W Olanow; S Fahn; M Muenter; H Klawans; H Hurtig; M Stern; I Shoulson; R Kurlan; J D Grimes; J Jankovic
Journal:  Mov Disord       Date:  1994-01       Impact factor: 10.338

View more
  3 in total

Review 1.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.

Authors:  Szabolcs Farkas; Katalin Nagy; Zhisheng Jia; Tibor Harkany; Miklós Palkovits; Sean R Donohou; Victor W Pike; Christer Halldin; Domokos Máthé; László Csiba; Balázs Gulyás
Journal:  Brain Res Bull       Date:  2012-03-07       Impact factor: 4.077

3.  Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study.

Authors:  Seoyoung Kim; Elena Younhye Ock; Jun Soo Kwon; Euitae Kim
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.